AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sangamo Therapeutics Soars 37.14% on Eli Lilly Deal
Generated by AI AgentAinvest Movers Radar
Friday, Apr 4, 2025 4:11 am ET1min read
Sangamo Therapeutics' stock surged 37.14% in pre-market trading on April 4, 2025, driven by a significant licensing agreement with
.Sangamo Therapeutics has entered into a licensing agreement with Eli
and Company, granting Lilly the rights to use Sangamo's proprietary capsid, STAC-BBB, for up to five potential disease targets. This capsid has shown strong blood-brain barrier penetration and neuronal transduction in nonhuman primates, making it a valuable tool for delivering genomic medicines to the central nervous system.Under the terms of the agreement, Sangamo will receive an $18 million upfront license fee and is eligible for up to $1.4 billion in additional licensed target fees and milestone payments, along with tiered royalties on potential net sales. This deal marks the third agreement with a pharmaceutical company since the discovery of STAC-BBB in March 2024, highlighting the growing industry interest in Sangamo's capsid delivery technology.
Sangamo Therapeutics is dedicated to developing genomic medicines for serious neurological diseases, leveraging its zinc finger epigenetic regulators and capsid discovery platform. The company's pipeline includes multiple partnered programs and opportunities for further collaboration and investment.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Dynavax (DVAX) Shares Plunge 1.70% Amid Regulatory and Legal Risks in Sanofi Deal
Dec.24 2025
Intuitive Machines Stock Plunges 12.04% on CEO Share Sale Q3 Loss Acquisition Risks
Dec.24 2025
Repare Therapeutics Dives 2.25% to 12-Month Low Amid Strategic Uncertainty *Key drivers: Pending XenoTherapeutics bid, Gilead asset sale reshape investor sentiment*
Dec.24 2025
Reviva Pharmaceuticals (RVPH) Plunge 55.93% as FDA Demands Additional Trial for Schizophrenia Drug
Dec.24 2025
Fermi Shares Plunge 7.21% to Monthly Low on AICA Termination, Legal Scrutiny
Dec.24 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet